I got COVID; I got a very high fever 103.3 was the highest I measured; I have been having the very heavy sweats during the night, general malaise, it started with a lot of pressure inside my lung that I could not breath; cough and the nasal congestion; I got a reaction on my nipple; I got a growth a benign growth on my left nipple; I just had symptoms like COVID or influenza; I have been having the very heavy sweats during the night, general malaise, it started with a lot of pressure inside my lung that I could not breath; I have been having the very heavy sweats during the night, general malaise, it started with a lot of pressure inside my lung that I could not breath; cough and the nasal congestion; This is a spontaneous report received from a contactable reporter(s) (Pharmacist) from product quality group. The reporter is the patient.  A 59 year-old female patient received bnt162b2 (BNT162B2), administered in arm left (Lot number: EW0196) at the age of 59 years as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose: 1, Lot: EW0177), administration date: May2021, for COVID-19 immunization. The following information was reported: COVID-19 (medically significant) with onset 23Dec2021, outcome "unknown", described as "I got COVID"; PYREXIA (non-serious) with onset 23Dec2021, outcome "unknown", described as "I got a very high fever 103.3 was the highest I measured"; DYSPNOEA (non-serious), HYPERHIDROSIS (non-serious), PULMONARY PAIN (non-serious) all with onset 23Dec2021, outcome "unknown" and all described as "I have been having the very heavy sweats during the night, general malaise, it started with a lot of pressure inside my lung that I could not breath";it started with a lot of pressure inside her lung that she could not breath and that was for the first day and then 'eatables' then to start the next day was starting to cough and the nasal congestion came like on day three. Her symptoms started on 23Dec. NASAL CONGESTION (non-serious), COUGH (non-serious) all with onset 23Dec2021, outcome "unknown" and all described as "cough and the nasal congestion"; BENIGN BREAST NEOPLASM (non-serious) with onset 23Dec2021, outcome "unknown", described as "I got a reaction on my nipple; I got a growth a benign growth on my left nipple"; INFLUENZA (non-serious) with onset 23Dec2021, outcome "unknown", described as "I just had symptoms like COVID or influenza". The patient underwent the following laboratory tests and procedures: pyrexia: 103.3, notes: I got a very high fever 103.3.  Clinical course: Pharmacist further stated, "In his case was that he got COVID although he has my two doses, he got COVID and he got a very high fever 103.3 was the highest he measured. He has been having the very heavy sweats during the night, general malaise, it started with a lot of pressure inside his lung that he could not breath and that was for the first day and then 'eatables' then to start the next day was starting to cough and the nasal congestion came like on day three. His symptoms started on 23Dec2021. Pharmacist stated, "In my case, he got it on the left arm and actually two days after he got a reaction on his nipple and we do not know, he got black a reaction and he had to have a biopsy on his nipple and that came two days after he got his first vaccine, it came out as benign growth, but it was very interesting that he got that immediately two days after the vaccination and his son, he think he also because we are right handed so got vaccinated on the left hand, on the left arm. Pharmacist further added, he got a growth a benign growth on his left nipple which was not there it's invisible and he got a biopsy done.; Sender's Comments: Based on the information provided and plausible temporal association, the causality between BNT162B2 and events cannot be completely excluded.  The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.